Eli Lilly reported early trial data for VERVE-102, its PCSK9 base-editing program acquired via the Verve Therapeutics buyout, showing a single infusion can reduce LDL cholesterol by as much as 62% in Phase 1. Lilly said the response was sustained for up to 18 months in the study and that no treatment-related serious adverse events were observed. The findings add clinical momentum to Lilly’s one-time gene-editing strategy for cardiovascular risk reduction, especially given that many patients struggle with adherence or tolerability on existing lipid-lowering regimens. Lilly’s disclosures position the program for later-stage development, with plans to advance toward Phase 3 if continued safety and efficacy signals hold up.